TRU

Gregory Renza

Q: How accurate are Gregory Renza's stock ratings?

About 53% of Gregory's ratings were profitable over a one-year hold, with an average return of +12.3% per rating, measured by 13Foresight from historical prices.

Q: How is Gregory ranked?

Gregory Renza is ranked #2651 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Truist Financial

Wall Street Analyst

★★☆☆☆

#2651

on 13Foresight · ranked by our own returns

53%

Success Rate

+11.1%

Average Return

72 of 136 calls profitable · +27.5% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 53% of Gregory Renza's ratings turned a profit when each position was held for 2 year — averaging +11.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

217 Buy 28 Hold 0 Sell

Gregory's Stock Coverage 37 ratings · 2026-09-28

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	2-Yr Return	vs S&P 500 ⓘ
VKTX Viking Therapeutics	Sep 23, 2026	BUY	Strong Buy +104.9% avg upside 31 analysts	$87.00 144.58% Upside	-14.6%	·
AMGN Amgen	Sep 23, 2026	HOLD	Buy -22.6% avg upside 57 analysts	—	+2.1%	·
ABVX Abivax SA Sponsored ADR	Sep 22, 2026	BUY	Strong Buy +46.4% avg upside 16 analysts	$151.00 65.89% Upside	-3.5%	·
NUVB Nuvation Bio	Sep 15, 2026	BUY	Strong Buy +132.3% avg upside 17 analysts	—	-1.0%	·
CATX Perspective Therapeutics	Sep 15, 2026	BUY	Strong Buy +338.2% avg upside 24 analysts	—	-7.7%	·
EXEL Exelixis	Sep 14, 2026	HOLD	Buy -27.0% avg upside 34 analysts	—	+3.5%	·
CGON CG Oncology, Inc.	Sep 10, 2026	BUY	Strong Buy +28.1% avg upside 17 analysts	—	-4.5%	·
MNKD MannKind	Sep 10, 2026	BUY	Buy +112.7% avg upside 22 analysts	—	-13.2%	·
RVMD Revolution Medicines	Sep 03, 2026	BUY	Strong Buy -1.4% avg upside 33 analysts	—	-2.8%	·
JAZZ Jazz Pharmaceuticals	Sep 01, 2026	BUY	Strong Buy +3.8% avg upside 35 analysts	—	-2.4%	·
IDYA IDEAYA Biosciences	Sep 01, 2026	BUY	Strong Buy +31.2% avg upside 29 analysts	—	-8.2%	·
VRDN Viridian Therapeutics	Sep 01, 2026	BUY	Strong Buy +71.7% avg upside 32 analysts	—	-11.1%	·
GILD Gilead Sciences	Aug 28, 2026	BUY	Strong Buy -21.6% avg upside 66 analysts	—	+3.3%	·
AAPG Ascentage Pharma Group International Unsponsored ADR	Aug 21, 2026	BUY	Strong Buy +211.9% avg upside 10 analysts	—	-12.6%	·
FULC Fulcrum Therapeutics	Aug 18, 2026	HOLD	Hold +167.4% avg upside 14 analysts	—	-3.4%	·
GMAB Genmab	Aug 12, 2026	BUY	Strong Buy +80.3% avg upside 27 analysts	—	-93.3%	·
AGIO Agios Pharma	Aug 11, 2026	BUY	Strong Buy +90.7% avg upside 29 analysts	—	+3.2%	·
ZYME Zymeworks	Aug 11, 2026	BUY	Strong Buy +26.0% avg upside 26 analysts	$32.00 20.59% Upside	+9.0%	·
ONC BeOne Medicines	Aug 06, 2026	BUY	Strong Buy +0.4% avg upside 28 analysts	$418.00 15.85% Upside	+9.4%	·
XNCR Xencor	Aug 06, 2026	BUY	Strong Buy +51.3% avg upside 27 analysts	—	+23.6%	·
BCYC Bicycle Therapeutics	Jul 31, 2026	HOLD	Strong Buy +555.6% avg upside 21 analysts	$7.00 89.94% Upside	-4.5%	·
REGN Regeneron	Jul 31, 2026	BUY	Strong Buy +0.3% avg upside 59 analysts	$772.00 2.05% Downside	+3.5%	·
NRIX Nurix Therapeutics	Jul 10, 2026	BUY	Strong Buy +39.0% avg upside 28 analysts	$34.00 47.67% Upside	-0.2%	·
ACAD ACADIA Pharmaceuticals	May 19, 2025	BUY	Strong Buy +74.3% avg upside 43 analysts	$26.00 25.80% Upside	-6.0%	·
ADCT ADC Therapeutics	May 14, 2025	BUY	Buy +306.8% avg upside 12 analysts	$8.00 529.92% Upside	-27.6%	·
INO Inovio Pharmaceuticals	May 13, 2025	HOLD	Buy +641.3% avg upside 19 analysts	$5.00 323.77% Upside	-38.5%	·
VRCA Verrica Pharmaceuticals	May 13, 2025	HOLD	Strong Buy +291.9% avg upside 9 analysts	$20.00 357.74% Upside	-16.0%	·
VSTM Verastem	May 13, 2025	BUY	Strong Buy +99.3% avg upside 24 analysts	$16.00 106.77% Upside	+3.8%	·
JSPR Jasper Therapeutics	May 12, 2025	BUY	Buy +4642.2% avg upside 18 analysts	$46.00 7452.10% Upside	-87.2%	·
PCRX Pacira Pharmaceuticals	May 08, 2025	HOLD	Buy +52.5% avg upside 22 analysts	$26.00 3.55% Upside	-6.7%	·
ATYR aTyr Pharma	May 07, 2025	BUY	Buy +2651.3% avg upside 17 analysts	$16.00 5146.00% Upside	-90.3%	·
SPRB Spruce Biosciences	May 06, 2025	HOLD	Strong Buy +113.5% avg upside 16 analysts	$37.50 22.97% Downside	-87.8%	·
CRMD Cormedix	May 06, 2025	BUY	Strong Buy +91.6% avg upside 13 analysts	$13.00 65.55% Upside	-31.1%	·
AVTX Avalo Therapeutics	Jun 26, 2023	HOLD	Strong Buy +240.9% avg upside 20 analysts	$180.00 1063.49% Upside	-96.0%	·
APRE Aprea Therapeutics	Mar 16, 2022	HOLD	Strong Buy +2905.6% avg upside 7 analysts	$80.00 10415.35% Upside	·	·
ITRMF Iterum Therapeutics	Nov 12, 2021	HOLD	Hold +716666566.7% avg upside 5 analysts	$15.00 1499999900.05% Upside	·	·
BIIB Biogen	Sep 08, 2015	BUY	Strong Buy +12.1% avg upside 53 analysts	$348.00 52.95% Upside	+5.7%	·

🔒 32 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Gregory Renza — Frequently Asked Questions

How accurate are Gregory Renza's stock ratings?

Based on the calls 13Foresight could measure, about 53% of Gregory's ratings were profitable over a one-year hold, with an average return of +12.3% per rating, or +19.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Gregory ranked on 13Foresight?

Gregory Renza is currently ranked #2651 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Gregory cover?

Gregory most recently has ratings on VKTX, AMGN, ABVX, NUVB, CATX, EXEL, CGON, MNKD, RVMD, JAZZ, IDYA, VRDN and 25 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Gregory Renza

Rating Distribution

Welcome to 13Foresight!